{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-326925","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.029950+00:00","generated_at":"2026-05-16T12:35:00.086137+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027","bullets":["Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.","Net proceeds ~$8.9M (~$10.3M if underwriters exercise full option), after underwriting discounts and expenses.","Cash runway extended into Q1 2027 based on net proceeds, existing cash, and expected $10M from ImmunoScape collaboration.","Underwriters have 30-day option to purchase up to 5,357,140 additional shares and 2,678,570 warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-326925","json":"https://secwatch.observer/filing/0001193125-25-326925.json","markdown":"https://secwatch.observer/filing/0001193125-25-326925.md","text":"https://secwatch.observer/filing/0001193125-25-326925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/0001193125-25-326925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/d213128d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:35:00.086137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e0e6906764f86e48fe537d01c60674a021fb8ec","claim":"Cue Biopharma, Inc. entered into Underwriting Agreement with H.C. Wainwright & Co., LLC (effective 2025-12-19).","evidence_excerpt":"On December 19, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525326925/0001193125-25-326925-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Effective","value":"2025-12-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}